These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

150 related articles for article (PubMed ID: 37405475)

  • 1. Preferences of German and Swiss melanoma patients for toxicities versus melanoma recurrence during adjuvant treatment (GERMELATOX-A-trial).
    Kähler KC; Hüning S; Nashan D; Meiss F; Rafei-Shamsabadi DA; Rissmann H; Colapietro C; Livingstone E; Maul LV; Heppt M; Hassel JC; Gutzmer R; Loquai C; Heinzerling L; Sachse MM; Bohne AS; Moysig L; Peters W; Rusch J; Blome C
    J Cancer Res Clin Oncol; 2023 Oct; 149(13):11705-11718. PubMed ID: 37405475
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Preferences of physicians for treatment-related toxicity vs. recurrence in melanoma (GERMELATOX-A): the doctors' perspective.
    Kähler KC; Gutzmer R; Angela Y; Livingstone E; Lodde G; Meiss F; Rafei-Shamsabadi DA; Weyer-Fahlbusch SS; Nashan D; Loquai C; Hassel JC; Sachse MMM; Maul LV; Heinzerling L; Heppt MV; Colapietro C; Rusch J; Blome C
    J Cancer Res Clin Oncol; 2024 May; 150(5):252. PubMed ID: 38743104
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Preferences of German melanoma patients for interferon (IFN) α-2b toxicities (the DeCOG "GERMELATOX survey") versus melanoma recurrence to quantify patients' relative values for adjuvant therapy.
    Kaehler KC; Blome C; Forschner A; Gutzmer R; Haalck T; Heinzerling L; Kornek T; Livingstone E; Loquai C; Maul LV; Lang BM; Schadendorf D; Stade B; Terheyden P; Utikal J; Wagner T; Hauschild A; Garbe C; Augustin M
    Medicine (Baltimore); 2016 Nov; 95(46):e5375. PubMed ID: 27861370
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Adjuvant treatment and outcome of stage III melanoma patients: Results of a multicenter real-world German Dermatologic Cooperative Oncology Group (DeCOG) study.
    Lodde GC; Hassel J; Wulfken LM; Meier F; Mohr P; Kähler K; Hauschild A; Schilling B; Loquai C; Berking C; Hüning S; Eckardt J; Gutzmer R; Reinhardt L; Glutsch V; Nikfarjam U; Erdmann M; Beckmann CL; Stang A; Kowall B; Galetzka W; Roesch A; Ugurel S; Zimmer L; Schadendorf D; Forschner A; Livingstone E
    Eur J Cancer; 2023 Sep; 191():112957. PubMed ID: 37487400
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Real-life data for first-line combination immune-checkpoint inhibition and targeted therapy in patients with melanoma brain metastases.
    Hilbers ML; Dimitriou F; Lau P; Bhave P; McArthur GA; Zimmer L; Kudura K; Gérard CL; Levesque MP; Michielin O; Dummer R; Cheng PF; Mangana J
    Eur J Cancer; 2021 Oct; 156():149-163. PubMed ID: 34454317
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Drug-induced sarcoidosis-like reaction in adjuvant immunotherapy: Increased rate and mimicker of metastasis.
    Chorti E; Kanaki T; Zimmer L; Hadaschik E; Ugurel S; Gratsias E; Roesch A; Bonella F; Wessendorf TE; Wälscher J; Theegarten D; Schadendorf D; Livingstone E
    Eur J Cancer; 2020 May; 131():18-26. PubMed ID: 32248071
    [TBL] [Abstract][Full Text] [Related]  

  • 7. MAPKinase inhibition after failure of immune checkpoint blockade in patients with advanced melanoma - An evaluation of the multicenter prospective skin cancer registry ADOREG.
    Kreft S; Glutsch V; Zaremba A; Schummer P; Mohr P; Grimmelmann I; Gutzmer R; Meier F; Pföhler C; Sachse MM; Meiss F; Forschner A; Haferkamp S; Welzel J; Terheyden P; Herbst R; Utikal J; Kaatz M; Weishaupt C; Kreuter A; Debus D; Duecker P; Sindrilaru A; Löffler H; Schley G; Weichenthal M; Schadendorf D; Ugurel S; Gesierich A; Schilling B
    Eur J Cancer; 2022 May; 167():32-41. PubMed ID: 35366571
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Immune checkpoint inhibition and targeted therapy for melanoma: A patient-oriented cross-sectional comparative multicentre study.
    Thiem A; Mashhadiakbar P; Cussigh C; Hassel JC; Grimmelmann I; Gutzmer R; Schlaak M; Heppt MV; Dücker P; Hüning S; Schulmeyer L; Schilling B; Haferkamp S; Ziemer M; Moritz RKC; Hagelstein V; Terheyden P; Posch C; Gaiser MR; Kropp P; Emmert S; Müller B; Tietze JK
    J Eur Acad Dermatol Venereol; 2023 May; 37(5):884-893. PubMed ID: 36433671
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Genetic characterization of advanced conjunctival melanoma and response to systemic treatment.
    Lodde GC; Jansen P; Möller I; Sucker A; Hassel JC; Forschner A; Eckardt J; Meier F; Reinhardt L; Kähler KC; Ziemer M; Schlaak M; Rahimi F; Schatton K; Meiss F; Gutzmer R; Pföhler C; Terheyden P; Schilling B; Sachse M; Heppt MV; Sindrilaru A; Leiter U; Zaremba A; Thielmann CM; Ugurel S; Zimmer L; Hadaschik E; Bechrakis NE; Schadendorf D; Westekemper H; Livingstone E; Griewank KG;
    Eur J Cancer; 2022 May; 166():60-72. PubMed ID: 35279471
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Factors Influencing the Adjuvant Therapy Decision: Results of a Real-World Multicenter Data Analysis of 904 Melanoma Patients.
    Lodde G; Forschner A; Hassel J; Wulfken LM; Meier F; Mohr P; Kähler K; Schilling B; Loquai C; Berking C; Hüning S; Schatton K; Gebhardt C; Eckardt J; Gutzmer R; Reinhardt L; Glutsch V; Nikfarjam U; Erdmann M; Stang A; Kowall B; Roesch A; Ugurel S; Zimmer L; Schadendorf D; Livingstone E
    Cancers (Basel); 2021 May; 13(10):. PubMed ID: 34065995
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The outweigh of toxicity versus risk of recurrence for adjuvant interferon therapy: a survey in German melanoma patients and their treating physicians.
    Kähler KC; Blome C; Forschner A; Gutzmer R; Hauschild A; Heinzerling L; Livingstone E; Loquai C; Müller-Brenne T; Schadendorf D; Utikal J; Wagner T; Augustin M
    Oncotarget; 2018 May; 9(40):26217-26225. PubMed ID: 29899854
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Real-world outcomes using PD-1 antibodies and BRAF + MEK inhibitors for adjuvant melanoma treatment from 39 skin cancer centers in Germany, Austria and Switzerland.
    Schumann K; Mauch C; Klespe KC; Loquai C; Nikfarjam U; Schlaak M; Akçetin L; Kölblinger P; Hoellwerth M; Meissner M; Mengi G; Braun AD; Mengoni M; Dummer R; Mangana J; Sindrilaru MA; Radmann D; Hafner C; Freund J; Rappersberger K; Weihsengruber F; Meiss F; Reinhardt L; Meier F; Rainer B; Richtig E; Ressler JM; Höller C; Eigentler T; Amaral T; Peitsch WK; Hillen U; Harth W; Ziller F; Schatton K; Gambichler T; Susok L; Maul LV; Läubli H; Debus D; Weishaupt C; Börger S; Sievers K; Haferkamp S; Zenderowski V; Nguyen VA; Wanner M; Gutzmer R; Terheyden P; Kähler K; Emmert S; Thiem A; Sachse M; Gercken-Riedel S; Kaune KM; Thoms KM; Heinzerling L; Heppt MV; Tratzmiller S; Hoetzenecker W; Öllinger A; Steiner A; Peinhaupt T; Podda M; Schmid S; Wollina U; Biedermann T; Posch C
    J Eur Acad Dermatol Venereol; 2023 May; 37(5):894-906. PubMed ID: 36433688
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Patient preferences for adjuvant interferon alfa-2b treatment.
    Kilbridge KL; Weeks JC; Sober AJ; Haluska FG; Slingluff CL; Atkins MB; Sock DE; Kirkwood JM; Nease RF
    J Clin Oncol; 2001 Feb; 19(3):812-23. PubMed ID: 11157035
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The survivorship experience for patients with metastatic melanoma on immune checkpoint and BRAF-MEK inhibitors.
    Lai-Kwon J; Khoo C; Lo S; Milne D; Mohamed M; Raleigh J; Smith K; Lisy K; Sandhu S; Jefford M
    J Cancer Surviv; 2019 Aug; 13(4):503-511. PubMed ID: 31165342
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Survival of melanoma patients treated with targeted therapy and immunotherapy after systematic upfront control of brain metastases by radiosurgery.
    Gaudy-Marqueste C; Dussouil AS; Carron R; Troin L; Malissen N; Loundou A; Monestier S; Mallet S; Richard MA; Régis JM; Grob JJ
    Eur J Cancer; 2017 Oct; 84():44-54. PubMed ID: 28783540
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Biologic subtypes of melanoma predict survival benefit of combination anti-PD1+anti-CTLA4 immune checkpoint inhibitors versus anti-PD1 monotherapy.
    Rose AAN; Armstrong SM; Hogg D; Butler MO; Saibil SD; Arteaga DP; Pimentel Muniz T; Kelly D; Ghazarian D; King I; Kamil ZS; Ross K; Spreafico A
    J Immunother Cancer; 2021 Jan; 9(1):. PubMed ID: 33483342
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Patient-reported outcomes in patients with resected, high-risk melanoma with BRAF
    Schadendorf D; Hauschild A; Santinami M; Atkinson V; Mandalà M; Chiarion-Sileni V; Larkin J; Nyakas M; Dutriaux C; Haydon A; Robert C; Mortier L; Lesimple T; Plummer R; Schachter J; Dasgupta K; Manson S; Koruth R; Mookerjee B; Kefford R; Dummer R; Kirkwood JM; Long GV
    Lancet Oncol; 2019 May; 20(5):701-710. PubMed ID: 30928620
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Impact of immune checkpoint inhibitors and targeted therapy on health-related quality of life of people with stage III and IV melanoma: a mixed-methods systematic review.
    Lai-Kwon J; Inderjeeth AJ; Lisy K; Sandhu S; Rutherford C; Jefford M
    Eur J Cancer; 2023 May; 184():83-105. PubMed ID: 36907021
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Prescription Patterns, Recurrence, and Toxicity Rates of Adjuvant Treatment for Stage III/IV Melanoma-A Real World Single-Center Analysis.
    Hoffmann M; Hayoz S; Özdemir BC
    Biology (Basel); 2022 Mar; 11(3):. PubMed ID: 35336796
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Discontinuation of BRAF/MEK-Directed Targeted Therapy after Complete Remission of Metastatic Melanoma-A Retrospective Multicenter ADOReg Study.
    Stege H; Haist M; Schultheis M; Fleischer MI; Mohr P; Meier F; Schadendorf D; Ugurel S; Livingstone E; Zimmer L; Herbst R; Pföhler C; Kähler K; Weichenthal M; Terheyden P; Nashan D; Debus D; Kaatz M; Ziller F; Haferkamp S; Forschner A; Leiter U; Kreuter A; Ulrich J; Kleemann J; Bradfisch F; Grabbe S; Loquai C
    Cancers (Basel); 2021 May; 13(10):. PubMed ID: 34065877
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.